PerkinElmer, Inc. (PKI) Bundle
Curious who's backing PerkinElmer-and why big money still believes in its playbook? With roughly 85% of shares in institutional hands as of late 2025, the ownership map reads like a who's who of asset managers: The Vanguard Group leads with about 11.7%, Capital Research Global Investors holds 9.44%, T. Rowe Price sits at 7.95%, Select Equity Group at 7.92%, BlackRock at 6.84% and State Street at 4.14%, and the March 31, 2023 filings show notable shifts-Vanguard up 1.97%, Capital Research down 7.93%, T. Rowe up 6.05%, Select Equity up 1.62%, BlackRock up 1.25% and State Street down 1.33%-all while the stock has slipped ~27% over the past year even as the Zacks consensus for current-year EPS ticked up 1.8% to $7.90 and investor interest grows around PerkinElmer's AI-driven diagnostics and life-sciences strategy; read on to unpack who is steering corporate governance, how portfolio moves signal confidence or caution, and what this concentrated ownership means for PKI's next chapter.
PerkinElmer, Inc. (PKI) - Who Invests in PerkinElmer, Inc. (PKI) and Why?
Institutional investors dominate PerkinElmer's shareholder base, holding approximately 85% of outstanding shares as of late 2025. That concentration signals broad professional conviction in PKI's strategy, recurring revenue model, and exposure to resilient end markets such as diagnostics, life sciences research, and environmental testing.- Scale investors (mutual funds, asset managers) favor PKI for predictable cash flow and high-margin consumables tied to lab workflows.
- Active fundamental managers prize PKI's pipeline of instrument upgrades, recurring services, and inorganic growth opportunities.
- Index and ETF investors provide passive demand given PKI's weighting in healthcare and industrial indices.
- Specialty healthcare/biotech investors allocate to PKI for exposure to diagnostics and genomic tools supporting long-term secular growth.
| Investor | Ownership (%) | Investor Type | Why They Invest |
|---|---|---|---|
| The Vanguard Group, Inc. | 11.70% | Index/Active mutual funds | Core holding for diversified equity exposure to healthcare & diagnostics; benefits from passive+active vehicles |
| Capital Research Global Investors | 9.44% | Active long-term growth manager | Long-horizon conviction in PKI's market position and secular demand for lab automation and diagnostics |
| T. Rowe Price Investment Management, Inc. | 7.95% | Active growth/value manager | Favorable view of revenue durability, margin expansion and R&D-driven product cycles |
| BlackRock, Inc. | 6.84% | Index/Active ETF & mutual funds | Broad ETF/index exposure plus active strategies backing operational efficiency and scale advantages |
| State Street Corporation | 4.14% | Index/ETF custodian & manager | Passive allocation in healthcare/industrial indices and stewardship for institutional clients |
- High institutional ownership (~85%) - reduces float volatility and signals confidence from professional managers.
- Recurring revenue mix from consumables, services and software - supports predictable topline and margin resilience.
- Market positioning across diagnostics, life-science instruments and environmental testing - diversified exposure to steady end markets.
- Attractive free cash flow generation and potential for share buybacks/dividend support - appeals to income- and total-return-focused funds.
PerkinElmer, Inc. (PKI) Institutional Ownership and Major Shareholders of PerkinElmer, Inc. (PKI)
PerkinElmer's shareholder base as of March 31, 2023 shows concentration among large asset managers and mutual fund complexes, indicating both strategic conviction and routine portfolio adjustments by institutional investors. The mix of increases and decreases in positions reflects active rebalancing around growth, valuation, and sector exposure considerations.- Vanguard Group, Inc.: increased holdings by 1.97% to own 11.70% of shares - largest reported stakeholder, signaling continued confidence in PerkinElmer's growth trajectory.
- Capital Research Global Investors: reduced stake by 7.93% to 9.44% - notable cut that may reflect portfolio rebalancing or strategic rotation.
- T. Rowe Price Investment Management, Inc.: increased holdings by 6.05% to 7.95% - a meaningful accumulation suggesting a positive outlook on near-/mid-term performance.
- Select Equity Group LP: increased stake by 1.62% to 7.92% - modest build consistent with conviction in PerkinElmer's market position.
- BlackRock, Inc.: increased holdings by 1.25% to 6.84% - broad-market allocator adding exposure, implying belief in operational efficiency or diversification need.
- State Street Corporation: decreased stake by 1.33% to 4.14% - small reduction possibly tied to index-fund flows or tactical reallocation.
| Institution | Ownership % (as of 3/31/2023) | Change in Holding (%) | Implication |
|---|---|---|---|
| Vanguard Group, Inc. | 11.70% | +1.97% | Largest shareholder - signals sustained confidence |
| Capital Research Global Investors | 9.44% | -7.93% | Significant reduction - likely portfolio rebalancing |
| T. Rowe Price Investment Management, Inc. | 7.95% | +6.05% | Substantial increase - positive performance outlook |
| Select Equity Group LP | 7.92% | +1.62% | Steady accumulation - confidence in positioning |
| BlackRock, Inc. | 6.84% | +1.25% | Incremental add - broad institutional support |
| State Street Corporation | 4.14% | -1.33% | Minor decrease - likely index/flow driven |
PerkinElmer, Inc. (PKI) - Key Investors and Their Impact on PerkinElmer, Inc. (PKI)
PerkinElmer's shareholder base is concentrated among several large institutional investors whose stakes and engagement materially shape capital allocation, strategic direction, and operational priorities. The largest holders - Vanguard, Capital Research, T. Rowe Price, Select Equity, BlackRock, and State Street - combine active stewardship, long-term capital, and tactical oversight that influence board engagement, M&A appetite, and efficiency programs.- Institutional concentration: Top six holders account for a significant minority of outstanding shares and coordinate (formally or informally) through proxy voting and governance dialogues.
- Governance pressure: Large passive and active managers push for board accountability, executive compensation alignment, and disclosure improvements.
- Strategic alignment: Growth-focused holders encourage R&D and M&A while index/efficiency-focused holders press for margin improvements and disciplined capital returns.
| Investor | Reported Stake (%) | Primary Influence | Typical Engagement/Actions |
|---|---|---|---|
| The Vanguard Group, Inc. | 11.70% | Corporate governance and shareholder-value enhancement | Proxy voting, board evaluations, stewardship letters, engagement on capital allocation |
| Capital Research Global Investors | 9.44% | Emphasis on sustainable, long-term growth | Long-term strategic dialogue, support for selective M&A and R&D investment |
| T. Rowe Price Investment Management, Inc. | 7.95% | Market-trend insight and industry adaptation | Analyst-driven recommendations, quarterly engagement on growth initiatives |
| Select Equity Group LP | 7.92% | Support for expansion and market diversification | Backing for inorganic growth, targeted growth-capital discussions |
| BlackRock, Inc. | 6.84% | Operational efficiency and cost management | Focus on margin expansion, ESG-aligned operational initiatives |
| State Street Corporation | 4.14% | Capital allocation and liquidity oversight | Engagement on buyback/dividend policy and reporting transparency |
- Collective voting power: These six investors together hold 47.99% of shares - substantial enough to sway contested votes and push for agreed-upon reforms.
- Balance of objectives: Growth advocates (Capital Research, Select Equity, T. Rowe) versus efficiency-focused managers (Vanguard, BlackRock, State Street) creates constructive tension that often yields calibrated strategies.
- Operational implications: Pressure for cost discipline from large index managers typically accelerates productivity programs; supportive active investors ensure reinvestment into high-return areas (e.g., diagnostics, instrumentation).
PerkinElmer, Inc. (PKI) - Market Impact and Investor Sentiment
PerkinElmer's stock has experienced a 27% decline over the past year, a move that has weighed on investor confidence even as select fundamental indicators show improvement. The Zacks Consensus Estimate for PerkinElmer's current-year earnings has increased 1.8% to $7.90 per share, signaling modestly improved analyst sentiment. Investors are parsing a mix of near-term macro pressures and company-specific catalysts - notably the firm's push into AI-augmented healthcare solutions and continued emphasis on diagnostics and life-sciences tools.- Recent 1-year price performance: -27% (reflects macro weakness and company-specific execution concerns)
- Zacks Consensus Estimate (current-year EPS): $7.90, up 1.8% (analyst revision strength)
- Investor thematic interest: AI in healthcare - seen as a growth catalyst for diagnostics, imaging, and lab automation
- Strategic activity watched by investors: acquisitions, partnerships, and integration progress
- Sector alignment: diagnostics and life sciences - attracts defensive/innovation-focused healthcare capital
- Overall investor tone: cautiously optimistic - focus on execution, margin recovery, and revenue growth from AI-enabled products
| Metric | Value |
|---|---|
| 1-Year Stock Change | -27% |
| Zacks Consensus EPS (Current Year) | $7.90 (+1.8%) |
| Primary Investor Drivers | AI adoption in healthcare; diagnostics & life-sciences exposure; M&A strategy |
| Investor Sentiment | Cautiously optimistic - conditional on execution and margin trends |
- Why some investors are buying: strategic exposure to diagnostics/life sciences; upside from AI-driven product lines; perceived valuation after a 27% pullback
- Why some investors remain cautious: integration risks from acquisitions; margin pressure and near-term macro headwinds; execution dependency to realize analyst upgrades
PerkinElmer, Inc. (PKI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.